Preliminary Results From IMVa??s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Mercka??s KeytrudaA® (pembrolizumab) and intermittent low dose cyclophosphamide (CPA) in patients with advanced and metastatic solid tumors, will be presented during the Immunotherapy of Cancer poster session at the European Society for Medical Oncology (ESMO) 2019 Congress, being held September 27 a?? October 1, 2019, in Barcelona, Spain.

Presentation Details

Poster Title: "Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours (preliminary results)a??

Presenter: Henry J Conter, M.D., Medical Oncology Director, William Osler Cancer Centre

Date and Time: Sept. 30, 2019, 12:00-13:00 CEST a?? poster will be displayed all day

Abstract Number: 1208P

Session Title: Immunotherapy of Cancer

Poster Display: Session 3, Poster Area a?? Hall 4
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »